The syndrome of impaired sensitivity to thyroid hormone, also known as syndrome of thyroid hormone resistance, is an inherited condition that occurs in 1 of 40,000 live births characterized by a reduced responsiveness of target tissues to thyroid hormone due to mutations on the thyroid hormone receptor. Patients can present with symptoms of hyperthyroidism or hypothyroidism. They usually have elevated thyroid hormones and a normal or elevated thyroid-stimulating hormone level. Due to their nonspecific symptomatic presentation, these patients can be misdiagnosed if the primary care physician is not familiar with the condition. This can result in frustration for the patient and sometimes unnecessary invasive treatment such as radioactive iodine ablation, as in the case presented herein.
T he syndrome of impaired sensitivity to thyroid hormone (ISTH) is a condition of decreased tissue sensitivity to thyroid hormone action usually caused by germline mutations of the thyroid hormone receptor beta (THRB) gene. Th e mutant receptor has lower binding affi nity for thyroid hormone and, as a consequence, serum thyroid-stimulating hormone (TSH) levels remain nonsuppressed despite elevated thyroid hormones ( 1 -3 ) . We present the case of a 66-year-old woman who was referred for evaluation of an abnormal thyroid function panel that suggested ISTH.
CASE REPORT
A 66-year-old woman was referred for evaluation of thyroid dysfunction. Her complaints were memory loss and intermittent gastrointestinal symptoms with alternating diarrhea and constipation attributed to irritable bowel syndrome. In 1998, she had been diagnosed with "a thyroid condition that no one was able to fi x." At that time, she had a goiter and was treated with radioactive iodine (I-131) and was subsequently started on thyroid replacement therapy. For nearly 30 years, she was seen by multiple physicians who continuously modifi ed her thyroid hormone replacement but had been unable to "normalize" her thyroid hormone levels, and this resulted in frustration 
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Ana Marcella Rivas, MD, and Joaquin Lado-Abeal, MD, PhD for the patient. Her family history was relevant for a son with "hypothyroidism."
Th e patient's thyroid function panels from 2009 to 2014 were reviewed and are presented in Table 1 . During this period of time she was on diff erent doses of thyroid replacement therapy, her TSH remained elevated despite normal or elevated free T4 levels. She also had magnetic resonance imaging of the head, which showed a possible right-sided pituitary microadenoma. A thyroid ultrasound showed a normal thyroid gland with some nonspecifi c nodules.
PCR amplifi cation of THRB gene exons 10, 9, and 8 followed by gene sequencing showed a heterozygous missense mutation C>A located at exon 10. Th e mutation caused a change in thyroid hormone receptor beta protein amino acid 453 proline to threonine, P453T ( Figure 1 ) .
We recommended that the patient resume thyroid hormone replacement with liothyronine 10 mg twice a day and levothyroxine 75 mcg daily; unfortunately, she was lost to follow up thereafter.
DISCUSSION
We describe a case of ISTH caused by a common germline mutation located at THRB exon 10 hot spot ( 4 ) . Th e patient went undiagnosed for many years. When reviewing her thyroid function tests, we noted a nonsuppressed serum TSH despite a normal or elevated free T4 level. Th ese abnormal values led us to suspect THRB mutation and proceed with genetic studies, which confi rmed the diagnosis. Th e diagnosis of ISTH requires a high degree of suspicion, and we therefore believe it is important for the general practitioner to be able to recognize the syndrome to avoid delay in diagnosis and unnecessary invasive treatments, such as thyroid surgery or radioactive iodine ablation. Th yroid hormone genomic actions are exerted by thyroid hormone binding mostly to nuclear receptors located in the nuclei and interaction with DNA to regulate the transcription of target genes. Most of the cases of ISTH are caused by mutations in the THRB gene located in chromosome 3, and these mutations most often clustered in three hot spots located in exons 8, 9, and 10. Th e mutant thyroid hormone receptor beta protein has either reduced affi nity for T3 or abnormal interaction with cofactors involved in thyroid hormone action, making the target tissues refractory to thyroid hormones ( 5 -7 ).
In 15% of cases of ISTH, a gene mutation is not identifi ed ( 6 ) . Mutations aff ecting thyroid hormone cell membrane transporters and thyroid hormone metabolism have now been described, and the concept of syndrome of reduced sensitivity to thyroid hormone is used to encompass any defect causing reduced eff ectiveness of the thyroid hormone ( 3 ) .
Th e clinical presentation of patients with THRB mutations is variable. Patients may present with symptoms of hyperthyroidism, hypothyroidism, or a combination of symptoms of thyroid hormone defi ciency and excess depending on the level of THRB and THRA gene expression in the target tissues ( 5 , 6 , 8 ) .
Symptoms tend to decrease with age, and patients eventually become clinically euthyroid. Goiter is one of the most common fi ndings for which patients seek medical attention. It's usually refractory and recurs after surgery or treatment with radioactive iodine. Other common complaints include tachycardia, learning disabilities, and hyperactivity ( 8 ) .
Th e classic pattern of thyroid function test that these patients present with is elevated thyroid hormones with nonsuppressed TSH in serum. Th e response of TSH to thyrotropin-releasing hormone is normal or exaggerated, and thyroidal radioiodine uptake may be elevated ( 5 ) .
ISTH can be diffi cult to diff erentiate from TSH-producing pituitary tumors, which present with a similar thyroid function profi le. A case of coexistence of both conditions has been reported ( 9 ) . TSH-producing pituitary tumors present elevated serum levels of T4, T3, and nonsuppressed TSH. In contrast to patients with ISTH who may be clinically euthyroid, patients with TSHomas usually present with symptoms of mild to severe hyperthyroidism and compression symptoms resulting from tumor growth ( 7 ) .
When treating these patients, one should concentrate on the patient's symptoms and clinical picture instead of aiming to normalize thyroid hormone levels ( 5 , 8 ) . Most patients, if left alone, adequately overcome the resistance by increased thyroid hormone secretion and therefore do not require treatment ( 8 , 10 ) .
Treating patients who present with normal TSH is more challenging; in these patients, administration of supraphysiological doses of thyroid hormone might be required and, if so, should be closely monitored. Patients who present with symptoms of hyperthyroidism should be treated symptomatically with 
